PRENETICS GLOBAL LTD PRE
SHS NEW · Common Stock · CUSIP G72245122
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $8.48.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2023 | 6 |
| Q1 2024 | 9 |
| Q2 2024 | 8 |
| Q3 2024 | 9 |
| Q4 2024 | 10 |
| Q1 2025 | 10 |
| Q2 2025 | 11 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2024 | 4 | 0 |
| Q2 2024 | 1 | 2 |
| Q3 2024 | 1 | 2 |
| Q4 2024 | 2 | 2 |
| Q1 2025 | 2 | 1 |
| Q2 2025 | 3 | 4 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2024 | $324.9k | $0 | 0.00 |
| Q4 2024 | $0 | $0 | — |
| Q1 2025 | $0 | $0 | — |
| Q2 2025 | $0 | $0 | — |
Biggest buyers
| BlackRock, Inc. | New | +24.8k |
| STEVENS CAPITAL PARTNERS | New | +17.4k |
| MORGAN STANLEY | Added | +6.8k |
Biggest sellers
| UBS Group AG | Reduced | -20.6k |
| Quinn Opportunity Partners LLC | Sold out | -12.3k |
| NOMURA HOLDINGS INC | Reduced | -11.7k |
| SBI Securities Co., Ltd. | Reduced | -56 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
No one currently above 5% in the filings since 19 Dec 2024.
Fell to 5% or below in the last year: Genetel Bioventures Ltd (3.3%, 2026-04-22)
Insider purchases and sales in Q2 2025
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2025.
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| PRUDENTIAL PLC 0.02% of their portfolio | 428.0k $3.6m | Unchanged |
| Aspex Management (HK) Ltd 0.06% of their portfolio | 346.1k $2.9m | Unchanged |
| NOMURA HOLDINGS INC 0.02% of their portfolio | 321.8k $2.7m | Reduced -11.7k |
| BlackRock, Inc. 0.00% of their portfolio | 24.8k $211.4k | New |
| STEVENS CAPITAL PARTNERS 0.05% of their portfolio | 17.4k $137.0k | New |
| MORGAN STANLEY 0.00% of their portfolio | 8.9k $76.0k | Added +6.8k |
| UBS Group AG 0.00% of their portfolio | 6.8k $58.1k | Reduced -20.6k |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 111 $945 | Unchanged |
| WOLVERINE ASSET MANAGEMENT LLC 0.00% of their portfolio | 1 $8 | Unchanged |
| SBI Securities Co., Ltd. 0.00% of their portfolio | 1 $9 | Reduced -56 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. — of their portfolio | 0 $0 | Unchanged |